Latest Restructuring News

Page 11 of 187
Gowing Bros has reported a $3.49 million FY2026 net loss, with Surf Hardware International remaining deeply loss-making and shopping centre values falling by $3 million. The diversified investment group maintained a fully franked 3 cents per share final dividend as cash declined and borrowings increased.
Victor Sage
Victor Sage
29 Oct 2026
Xref reported A$4.7 million of unaudited Q1 FY2027 revenue and positive EBITDA of A$0.6 million, as its newer platform generated 48% revenue growth. Trust Marketplace checks, Pulse surveys and employee lifecycle products all recorded sharp increases, while stronger liquidity is supporting renewed marketing investment.
Victor Sage
Victor Sage
29 Oct 2026
Tesoro Gold has secured A$40 million from institutional and sophisticated investors to fund development, permitting and exploration at its El Zorro project in Chile. The company will also seek to acquire the remaining minority interest in its Chilean subsidiary, lifting effective project ownership to 95.4%.
Maxwell Dee
Maxwell Dee
29 Oct 2026
BetMakers delivered a step-change in Q1 FY27 profitability, with constant-currency revenue rising 16.3% and adjusted EBITDA climbing 176% to $5.9 million. Positive operating cash flow and stronger margins add weight to the company’s technology-led growth story, although the figures remain unaudited.
Sophie Babbage
Sophie Babbage
29 Oct 2026
Titomic has strengthened its balance sheet with A$16.5 million in new equity and approval for a further US$10.3 million EXIM loan, while reporting more than A$11.8 million in orders since September. The progress comes with a sharper funding test: quarter-end cash was A$18.1 million after a A$10.4 million operating outflow, and the EXIM facility remains undrawn.
Victor Sage
Victor Sage
29 Oct 2026
Suncorp expects FY27 gross written premium growth of around 3%, despite losing a $125 million commercial contract and facing a weaker New Zealand dollar. The insurer maintained its forecast for an underlying insurance trading result margin in the top half of its 10-12% target range and confirmed a $250 million buyback is underway.
Victor Sage
Victor Sage
29 Oct 2026
Paradigm Biopharmaceuticals has secured court approval to delay its second creditors meeting until 27 January 2027, giving administrators more time to resolve outstanding matters. The meeting and administrators’ report could still arrive earlier, potentially within weeks.
Victor Sage
Victor Sage
28 Oct 2026
Dexus has forecast lower FY27 earnings while refocusing its business on office, industrial, retail and selected alternatives. The ASX-listed real estate group is also targeting more than A$2 billion of capital release, but remains exposed to infrastructure fund liquidity issues and the unresolved APAC appeal.
Eva Park
Eva Park
28 Oct 2026
Veris is using its FY26 results and first-quarter trading update to make the case that its transformation from surveyor to digital and spatial advisory firm is gaining traction. Revenue and underlying EBITDA rose, while the planned Aurecon acquisition adds a near-term test of whether the strategy can convert into stronger earnings.
Victor Sage
Victor Sage
28 Oct 2026
ASF Group finished FY2026 with A$5.19 million in cash, no outstanding borrowings and a materially stronger net asset position after selling several investments. But the A$4.09 million profit was still largely disposal-led, while operating cash flow remained negative and recurring revenue declined.
Victor Sage
Victor Sage
27 Oct 2026
TALi Digital has appointed William Hamilton as chief executive and managing director, placing the former DigitalX executive at the centre of its Datasphere commercialisation push. The leadership change also moves Dr David Brookes to non-executive chair and includes a proposed performance-rights package subject to shareholder approval.
Victor Sage
Victor Sage
27 Oct 2026
Cynata Therapeutics ended September with just A$175,000 in cash after a A$1.316 million quarterly operating drain, but says sweeping cuts and fresh funding could extend its runway into FY2028. The biotech has now reduced its workforce to zero, repaid its R&D loan and shifted focus to finding value for its Cymerus platform.
Ada Torres
Ada Torres
27 Oct 2026

Browse the archive

Full archive